The Fertility Enhancement study is being conducted at the Mayo Clinic in
To date, InSightec has reported 54 pregnancies, 22 deliveries with 11 ongoing pregnancies with women who previously underwent the ExAblate procedure.
About ExAblate(R) 2000
ExAblate is the first system to use the MR guided focused ultrasound technology that combines MRI - to visualize the body anatomy, plan the treatment and monitor treatment outcome in real time - and high intensity focused ultrasound to thermally ablate tumors inside the body non-invasively. MR thermometry, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared. The ExAblate system was approved by the U.S. Food and Drug Administration in 2004 as a treatment for symptomatic uterine fibroids. Over 4,500 women have been treated worldwide to date. ExAblate(R) 2000 received the European CE Mark certification for pain palliation of bone metastases in June 2007.
InSightec Ltd. is a privately held company owned by Elbit Imaging,
General Electric, MediTech Advisors, LLC and employees. It was founded in
1999 to develop the breakthrough MR guided Focused Ultrasound technology and
transform it into the next generation operating room. Headquartered near
Haifa, Israel, the company has over 160 employees and has invested more th
|SOURCE InSightec Ltd|
Copyright©2009 PR Newswire.
All rights reserved